Jazz Pharmaceuticals Competitors and Similar CompaniesClear all

Jazz Pharmaceuticals's competitors and similar companies include UCB, Kyverna Therapeutics, AlzProtect and CaaMTech.

	Jazz Pharmaceuticals Jazz Pharmaceuticals is a biopharmaceutical company engaged in developing and marketing medicines for sleep disorders, epilepsy, and oncology.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Kyverna Therapeutics Kyverna Therapeutics is a pharmaceutical company that generates treatments and potential cures for autoimmune diseases.	AlzProtect AlzProtect is a biopharmaceutical company discovering and developing drug candidates for the treatment of neurodegenerative diseases.	CaaMTech CaaMTech is a drug discovery company that creates and optimizes psychedelic drugs to treat mental health conditions.
Founding Date	Founding Date 2003	Founding Date 1928	Founding Date 2018	Founding Date 2007	Founding Date 2019
Type	Type Public	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare drug development mental health oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare bioengineering drug development pharma	Tags Healthcare bioengineering drug development pharma	Tags Healthcare bioengineering drug development mental health pharma
Locations	Locations Dublin, IE HQ Mississauga, CA Vancouver, CA Lyon, FR München, DE Roscommon, IE Villa Guardia, IT see more	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations Emeryville, US HQ	Locations Loos, FR HQ Loos, FR	Locations Issaquah, US HQ
Employees	Employees 2,800	Employees 9,052	Employees 84	Employees 1011% increase	Employees 9
Valuation ($)	Valuation ($) 6.9 b	Valuation ($) 34.3 b	Valuation ($) 230.8 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $4.3b (FY, 2025)	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Net income	Net income ($356.1m) (FY, 2025)	Net income €1.6b (FY, 2025)	Net income ($161.3m) (FY, 2025)	Net income N/A	Net income N/A
Funding
Latest funding round	Latest funding round N/A	Latest funding round N/A	Latest funding round N/A	Latest funding round $ 17.1m (over 8 years ago)	Latest funding round $ 22m (over 4 years ago)
Total funding raised	Total funding raised $ 384.1m	Total funding raised N/A	Total funding raised $ 25m	Total funding raised $ 19.8m	Total funding raised $ 22m